What is the efficacy of rituximab for the treatment of autoimmune hemolytic anemia (AIHA)?

Updated: May 27, 2021
  • Author: Srikanth Nagalla, MD, MS, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Increasing evidence supports the use of rituximab in AIHA, particularly warm antibody AIHA. [45, 45] Results of a phase III trial in 64 patients support its use as first-line therapy for warm AIHA, in combination with corticosteroids. Birgens et al reported that after 12 months, a satisfactory response was observed in 75% of the patients treated with rituximab and prednisolone, but in 36% of those given prednisolone alone (P = 0.003). After 36 months, about 70% of the patients who had received rituximab and prednisolone were still in remission, compared with about 45% of those in the prednisolone group. [43]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!